Decoy Therapeutics Book Value Per Share Growth & History (DCOY)
Decoy Therapeutics's book value per share was $11.07 for fiscal 2025.
View full Decoy Therapeutics company overviewDecoy Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.07 | -$4.66 | −29.64% |
| 2024 | 2024-12-31 | $15.73 | -$145.28 | −90.23% |
| 2023 | 2023-12-31 | $161.02 | -$391.10 | −70.84% |
| 2022 | 2022-12-31 | $552.12 | -$2,014.44 | −78.49% |
| 2021 | 2021-12-31 | $2,566.56 | -$224.21 | −8.03% |
| 2020 | 2020-12-31 | $2,790.78 | -$4,242.14 | −60.32% |
| 2019 | 2019-12-31 | $7,032.91 | $8,907.92 | — |
| 2018 | 2018-12-31 | -$1,875.00 | -$1,386.33 | — |
| 2017 | 2017-12-31 | -$488.67 | -$11,092.30 | — |
| 2016 | 2016-12-31 | $10,603.63 | -$6,957.39 | −39.62% |
| 2015 | 2015-12-31 | $17,561.03 | $26,409.30 | — |
| 2014 | 2014-12-31 | -$8,848.27 | — | — |
Decoy Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.12 | $13.97 | — |
| Q1 2026 | 2026-03-31 | $7.29 | $6.84 | +1535.97% |
| Q4 2025 | 2025-12-31 | $11.07 | -$4.66 | −29.64% |
| Q3 2025 | 2025-09-30 | $4.50 | -$25.93 | −85.22% |
| Q2 2025 | 2025-06-30 | -$5.85 | -$61.39 | — |
| Q1 2025 | 2025-03-31 | $0.45 | -$101.01 | −99.56% |
| Q4 2024 | 2024-12-31 | $15.73 | -$145.28 | −90.23% |
| Q3 2024 | 2024-09-30 | $30.42 | -$154.85 | −83.58% |
| Q2 2024 | 2024-06-30 | $55.54 | -$245.51 | −81.55% |
| Q1 2024 | 2024-03-31 | $101.46 | -$168.66 | −62.44% |
| Q4 2023 | 2023-12-31 | $161.02 | -$391.10 | −70.84% |
| Q3 2023 | 2023-09-30 | $185.27 | -$700.54 | −79.08% |
| Q2 2023 | 2023-06-30 | $301.05 | -$1,349.20 | −81.76% |
| Q1 2023 | 2023-03-31 | $270.12 | -$1,875.55 | −87.41% |
| Q4 2022 | 2022-12-31 | $552.12 | -$2,014.44 | −78.49% |
| Q3 2022 | 2022-09-30 | $885.81 | -$1,945.30 | −68.71% |
| Q2 2022 | 2022-06-30 | $1,650.25 | -$1,420.05 | −46.25% |
| Q1 2022 | 2022-03-31 | $2,145.67 | -$1,123.88 | −34.37% |
| Q4 2021 | 2021-12-31 | $2,566.56 | -$224.21 | −8.03% |
| Q3 2021 | 2021-09-30 | $2,831.11 | -$286.47 | −9.19% |
| Q2 2021 | 2021-06-30 | $3,070.31 | -$382.32 | −11.07% |
| Q1 2021 | 2021-03-31 | $3,269.55 | -$686.34 | −17.35% |
| Q4 2020 | 2020-12-31 | $2,790.78 | -$4,242.14 | −60.32% |
| Q3 2020 | 2020-09-30 | $3,117.58 | -$4,655.34 | −59.89% |
| Q2 2020 | 2020-06-30 | $3,452.63 | $3,331.00 | +2738.70% |
| Q1 2020 | 2020-03-31 | $3,955.88 | $3,668.73 | +1277.63% |
| Q4 2019 | 2019-12-31 | $7,032.91 | $8,907.92 | — |
| Q3 2019 | 2019-09-30 | $7,772.92 | $8,019.90 | — |
| Q2 2019 | 2019-06-30 | $121.63 | $318.16 | — |
| Q1 2019 | 2019-03-31 | $287.15 | -$3,362.92 | −92.13% |
| Q4 2018 | 2018-12-31 | -$1,875.00 | -$1,386.33 | — |
| Q3 2018 | 2018-09-30 | -$246.99 | -$6,431.80 | — |
| Q2 2018 | 2018-06-30 | -$196.54 | -$7,916.50 | — |
| Q1 2018 | 2018-03-31 | $3,650.07 | -$5,546.03 | −60.31% |
| Q4 2017 | 2017-12-31 | -$488.67 | -$11,092.30 | — |
| Q3 2017 | 2017-09-30 | $6,184.82 | -$5,800.91 | −48.40% |
| Q2 2017 | 2017-06-30 | $7,719.97 | -$6,076.06 | −44.04% |
| Q1 2017 | 2017-03-31 | $9,196.10 | -$6,573.20 | −41.68% |
| Q4 2016 | 2016-12-31 | $10,603.63 | -$6,957.39 | −39.62% |
| Q3 2016 | 2016-09-30 | $11,985.73 | -$7,034.71 | −36.99% |
| Q2 2016 | 2016-06-30 | $13,796.03 | -$6,859.96 | −33.21% |
| Q1 2016 | 2016-03-31 | $15,769.30 | -$6,336.00 | −28.66% |
| Q4 2015 | 2015-12-31 | $17,561.03 | $26,409.30 | — |
| Q3 2015 | 2015-09-30 | $19,020.44 | — | — |
| Q2 2015 | 2015-06-30 | $20,655.99 | — | — |
| Q1 2015 | 2015-03-31 | $22,105.30 | — | — |
| Q4 2014 | 2014-12-31 | -$8,848.27 | — | — |
Decoy Therapeutics book value per share trends
Over the last five fiscal years, Decoy Therapeutics's book value per share decreased from $2,790.78 to $11.07, a change of -$2,779.71. The latest reported quarter, Q2 2026, shows $8.12.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Decoy Therapeutics source filings ↗